The presentation of human leukocyte antigens (HLA) class I requires the coordinated expression of numerous components involved in antigen presentation. Tumor cells may alter the antigen presentation by HLA class I, allowing them to evade antitumor immunity. In many cases, the lack of antigen presentation can be attributed to the downregulation of genes needed for antigen processing, such as the transporters associated with antigen processing (TAP) 1, and the proteasomal component, low molecular weight proteins (LMP) 2. The TAP1 and LMP2 genes are transcribed from a shared bidirectional promoter containing an interferon (IFN)-c-response factor element; thus, the IFN-c-signal strongly induces both TAP1 and LMP2 expression. Low molecular weight proteins2-deficient mice exhibited the development of uterine leiomyosarcomas. Here, the differential responsiveness to IFN-c of the SKN human uterine leiomyosarcomas cell line was investigated. We now identify the G871E mutation in the ATP-binding region of Janus kinases 1, suggesting that the loss of TAP1 and LMP2 induction is a defect in the earliest steps of the IFN-csignal pathway, resulting in the inability of SKN cells to upregulate the antigen-processing pathway. Understanding the mechanisms by which these tumors circumvent cytokine signalling, thereby evading antitumor-specific immunity, would greatly aid the efficacy of immunotherapy for treating uterine leiomyosarcomas.
Introduction
The ability of tumor cells to present tumor-associated antigens on the cell surface through major histocompatibility complex (MHC) class I molecules is required for the generation of an effective antitumor-specific antigen cytotoxic T-lymphocyte (CTL) response. Interferon (IFN)-g-inducible genes, for instance the proteasome subunits, low molecular weight proteins (LMP)2, LMP7, LMP10 and the antigen transporters, transporters associated with antigen processing (TAP) 1 and TAP2, appear to be obligatory for the T-cell target recognition of tumors (Driscoll et al., 1993; Gaczynska et al., 1993; Belich et al., 1994; Momburg et al., 1994a, b; Groettrup et al., 1997; Seliger et al., 2000) . Many tumor cells unfortunately have lost this ability, thereby evading CTL-mediated immune surveillance and elimination (Garrido et al., 1997; Seliger et al., 2000; Dunn et al., 2002; Miyagi et al., 2003; Atkins et al., 2004) . The defective antigen presentation by MHC class I is attributed to the downregulation of several genes required for antigen processing or presentation, such as TAP1 and TAP2, and LMP2 and LMP7 (Singal et al., 1996; Dovhey et al., 2000; Cabrera et al., 2003) . Inactivation of the TAP1/LMP2 genes has been demonstrated in multiple distinct tumor types, and is associated with malignant transformation and disease progression (Dovhey et al., 2000) .
Interferon-g and lymphocytes prevent primary tumor development, therefore exhibiting a tumor suppressor role in the immune response (Kaplan et al., 1998; Shankaran et al., 2001) . The IFN-g-inducible TAP expression and function are involved in augmenting MHC class I-restricted tumor-associated antigen-specific CTL recognition (Kaplan et al., 1998; Shankaran et al., 2001) . The immuno-proteasome, the proteolytic machinery of the ubiquitin/ATP-dependent pathway, has a relevant role in many processes crucial for the cell physiology and cellular processes as diverse as cell cycle progression and the gene expression of numerous proinflammatory cytokines (Maniatis, 1999) .
The TAP1 and LMP2 genes are transcribed from a shared bidirectional promoter, which has three known sequences located at the TAP1 proximal region: (a) IFN response factor element (IRF-E); (b) nuclear factor kB (NF-kB)-like binding site; and (c) SP-1-binding site (Wright et al., 1995; White et al., 1996; Brucet et al., 2004) . Interferon-regulatory factor 1 (IRF-1) directly mediates the IFN-g induction of TAP1 and LMP2 by binding at the IRF-E (Harada et al., 1993; White et al., 1996; Brucet et al., 2004) . After binding of IFN-g to the type II IFN receptor, Janus kinase 1 (JAK1) and JAK2 are activated and phosphorylate signal transducer and activator of transcription 1 (STAT1) on the tyrosine residue at position 701 (Tyr701) (Ramana et al., 2002) . The phospho-STAT1 forms homodimers that translocate to the nucleus and bind IFN-activated sequence (IFN-g-activated site) elements, which are present in the promoters of IFN-g-regulated genes (White et al., 1996; Chatterjee-Kishore et al., 2000; Brucet et al., 2004; Platanias, 2005) .
We reported that LMP2 knockout mice exhibit a defect in proteasome function, and LMP2 knockout female mice are shown to develop uterine leiomyosarcomas, with a disease prevalence of 36% by 12 months of age (Van Kaer et al., 1994; Hayashi and Faustman, 2002) . The function of LMP2 is tissue specific and has an essential role for MHC class I-mediated tumor rejection by CTLs (Van Kaer et al., 1994) . It would be useful to determine whether the loss of TAP1 and LMP2 expression are probably attributable to deficiencies of these upregulatory factors on the development of spontaneous human uterine leiomyosarcomas. Recent reports, including experiments with LMP2 knockout mice, suggest that INF-g-induced restoration of antigenprocessing machinery, such as TAP1 and LMP2, improves antitumor-specific antigen CTL recognition in some patients; thus, approaches to activate this pathway may be of benefit to patients with TAP and LMP deficiencies.
As the importance and involvement of the IFN-gsignal pathway in the transcriptional regulation of the TAP1/LMP2 promoter have been established, we demonstrate that the defective TAP1 and LMP2 expression is attributable to G871E mutation in the ATP-binding region of JAK1 in uterine leiomyosarcoma cells. Discerning the IFN-g-signal pathway, including TAP1 and LMP2 transcriptional regulation in tumor cells, will provide essential information for the development of genetic and immunotherapeutic strategies to enhance human leukocyte antigens (HLA) class I antigen expression to combat cancer.
Results
Non-induction of TAP1 and LMP2 expression by interferon-g in human uterine leiomyosarcomas cells The LMP2-deficient mice exhibited the development of uterine leiomyosarcomas (Hayashi and Faustman, 2002) ; furthermore, it must therefore be demonstrated whether human uterine leiomyosarcomas show the weak expression of TAP1 and LMP2. The effects of IFN-g on TAP1 and LMP2 expression were examined by immunoblotting with four cell lines (Figure 1a ). TAP1 Figure 1a ). The expression of other IFN-g-inducible genes, LMP7 and LMP10, were not induced by IFN-g treatment in SKN cells (Supplementary Figure 1 ). The SKN cells had identical b2-m and bactin expressions when compared with both HeLa, HeLa.S3 cells and Hu.USMC as the control, suggesting that the step for preparation of the extract was not involved in the non-induction of TAP1 and LMP2 expression following IFN-g treatment. This amount of IFN-g was sufficient to maximally induce the shared bidirectional promoter for both TAP1 and LMP2 genes in both HeLa, HeLa.S3 cells and Hu.USMC ( Figure 1a ). Increasing the amount of IFN-g to 500 U/ ml did not noticeably induce TAP1 and LMP2 expression in SKN cells (data not shown). Thus, the SKN cells lost their ability to upregulate TAP1 and LMP2 expression following IFN-g treatment.
To verify the non-induction of TAP1 and LMP2 expression following IFN-g treatment, reverse transcription-polymerase chain reaction (RT-PCR) analysis was performed using four cell lines (Figure 1b) . Interferon-g treatment did not conspicuously induce the expression of mRNA for TAP1 and LMP2 in SKN cells, although the expression of mRNA for either TAP1 or LMP2 induced by IFN-g treatment was clearly detected in HeLa, HeLa.S3 cells and Hu.USMC (Figure 1b) . The expression of mRNA for the b2-m and b-actin control was detected in all the cells tested at a similar basal expression level, suggesting that the step for the preparation of total RNA was not involved in the non-induction of TAP1 and LMP2 expression following IFN-g treatment (Figure 1b) . Fluorescein-activated cell sorting (FACS) analysis furthermore showed the surface expression of b2-m on all the cells (Supplementary Figure 2) . The immunohistochemistry (IHC) experiments demonstrated that although normal uterine smooth muscle cells (N.USMC) markedly expressed LMP2 in six cases, uterine leiomyosarcoma cells did not (Figure 1c) . The results from IHC strongly supported the non-inducibility of TAP1 and LMP2 in SKN cells. To obtain further evidence showing the presence of mutations in the shared bidirectional promoter for TAP1 and LMP2 genes, the DNA fragment of the promoter was amplified and was then directly sequenced. Comparison of the DNA sequence from the shared promoter obtained from SKN cells and normal promoter region (Locus, counting number, NT_086690) demonstrated the absence of mutation (data not shown).
Loss of interferon-g-induced shared bidirectional promoter activity for TAP1 and LMP2 genes The IRF-1 binds directly to a cis-acting element called IRF-E in the shared bidirectional promoter for TAP1 and LMP2 genes (Wright et al., 1995; White et al., 1996; Dovhey et al., 2000; Brucet et al., 2004) . The IRF-E is located upstream of the NF-kB-like binding site and GC1 box, as represented diagrammatically in Figure 2 . The IRF-E is shown to be required for TAP1 and LMP2 upregulation following IFN-g treatment (Wright et al., 1995; White et al., 1996; Dovhey et al., 2000; Brucet et al., 2004) . To determine whether IFN-g clearly activates the TAP1/LMP2 shared bidirectional promoter in the SKN cells, both SKN cells and HeLa cells were transiently transfected with TAP1 and LMP2 wt or The nuclear extracts were prepared from HeLa, HeLa.S3 and SKN cells treated with IFN-g (250 U/ml) for the individual times indicated in the figure, and 50 mg of the nuclear extracts were resolved by 10% sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE). The expression levels of IRF1, IRF2 and bactin were examined by immunoblot analysis with appropriate antibodies. The DNA-binding activities of IRF1 and IRF2 were examined by electrophoretic mobility shift assay (EMSA) with the appropriate DNA probes indicated in the Materials and methods section of this manuscript. (b) Whole cell extracts were prepared from HeLa, HeLa.S3 and SKN cells treated with IFN-g (250 U/ml) for the individual times indicated in the figure, and 50 mg of whole cell extracts were resolved by 10% SDS-PAGE. The expression levels of STAT1, phospho-STAT1 and b-actin were examined using immunoblot analysis with the appropriate antibodies indicated in the figure. The DNA-binding activities of STAT1 were examined by EMSA with the appropriate DNA probes indicated in the Materials and methods section of this manuscript. The expression levels of b-actin were examined using the cytosolic extracts prepared from all tested cells, and the immunoblot analysis was performed using the standard procedure. Defect in the IFN-g-induced JAK1 kinase activity in SKN cells. (c) Whole cell extracts were prepared from HeLa, HeLa.S3 and SKN cells treated with IFN-g (250 U/ml) for the individual times indicated in the figure, and 50 mg of whole cell extracts were resolved with 10% SDS-PAGE. The expression levels of IFN-gR1, JAK1, JAK2 and b-actin were examined by immunoblot analysis with appropriate antibodies. (d) Whole cell extracts were prepared from HeLa, HeLa.S3 and SKN cells treated with IFN-g (250 U/ml) for the individual times indicated in the figure, and total whole cell extracts were immunoprecipitated with JAK1-and JAK2-specific antibodies, as already described. The immunoprecipitated-pellets were resolved with 10% SDS-PAGE, and then the immunoblot analyses were performed with an antiphosphotyrosine-specific antibody. The expression levels of b-actin were examined using the cytosolic extracts prepared from all tested cells, the immunoblot analysis was performed using the standard procedure.
Impaired JAK1 activation in uterine leiomyosarcoma cells T Hayashi et al three cell lines stimulated or unstimulated with IFN-g for the individual times. The migrating-specific complexes (indicated as IRF -2) were observed with the all tested extracts (Figure 3a) . Nuclear extracts from 1 h IFN-g-induced HeLa and HeLa.S3 cells produced an additional prominent complex (indicated as IRF-1), but SKN nuclear extracts did not (Figure 3a) . Antibody-blocking experiments confirmed the IRF-1-and IRF-2-binding activities in untreated and IFN-g-treated extracts (Supplementary Figure 3) .
Loss of interferon-g-mediated STAT1 activation in SKN cells
The loss of IFN-g-induced IRF-1 expression led us to examine where in the pathway the defect may reside. In the IFN-g-induced signal-cascade, IRF-1 is transcriptionally upregulated by IFN-g treatment through STAT1 activation. The IFN-g-induced JAK kinase activity directly phosphorylates STAT1, and the phospho-STAT1 plays a key role as a transcription factor for IRF-1 gene expression. In order to examine IFN-ginduced STAT1 activation, immunoblotting was carried out. Whole cell lysates prepared from the three IFN-gtreated cell lines were run on sodium dodecyl sulfatepolyacrylamide gel (SDS-PAGE) and blotted with anti-STAT1 or antiphospho-STAT1 (Tyr701) antibodies. A similar level of STAT1 was detected in untreated HeLa, HeLa.S3 and SKN cells (Figure 3b ). Although IFN-g treatment dramatically induced the phospho-STAT1 both in HeLa and HeLa.S3 cells, the research result showed complete absence of phospho-STAT1 in SKN cells (Figure 3b ). To verify the IFN-g-induced STAT1 DNA-binding activity in all tested cells, EMSA was performed with nuclear extracts prepared from three types of cells treated with 250 U/ml of IFN-g for the individual times. Electrophoretic mobility shift assay showed that the DNA-binding activity of phospho-STAT1 was dramatically detected in HeLa and HeLa.S3 cells, whereas the SKN cells had undetectable STAT1/DNA complexes ( Figure 3b ). To specifically identify the complex of protein with the DNA, the mutant DNA probes were used in EMSA. Incubation of the nuclear extract with the mutant DNA probes resulted in no significant DNA/protein complexes (Supplementary Figure 3) . Thus, these research findings revealed that SKN cells lacked functional IFN-g-induced STAT1 activation.
Defective interferon-g-induced JAK1 phosphorylation activity in SKN cells
The IFN-g-mediated tyrosine (Tyr701) phosphorylation activity of JAK1 and JAK2 significantly induces STAT1 activation. In order to examine the expressions and IFN-g-mediated phosphorylation status of both JAK1 and JAK2, immunoblotting was performed with the appropriate antibodies. The results from immunoblotting showed that although JAK2 was equally expressed in all tested cell lines, JAK1 had a slightly lower expression in SKN cells in comparison with the HeLa and HeLa.S3 cells (Figure 3c ). To investigate the IFN-ginduced JAK1 and JAK2 kinase activity, immunoprecipitation analyses with whole cell lysates prepared from cells stimulated with IFN-g for the individual times were performed with either JAK1-and JAK2-specific antibodies and probed with an antiphosphotyrosine antibody. The IFN-g-induced tyrosine phosphorylation of JAK2 was dramatically detected in all cell lines tested (Figure 3d ). On the other hand, the IFN-g-induced tyrosine phosphorylation of JAK1 was not detectable in SKN cells, whereas it was clearly found in HeLa and HeLa.S3 cells (Figure 3d) . Thus, the defect in the IFN-ginduced JAK1 activity resulted in an impaired IFN-gmediated signal pathway. To establish whether the lack of IFN-gR1 chain expression, which is the essential receptor for the IFN-g signal pathway, may be responsible for the absence of the IFN-g-mediated signal cascade, immunoblotting with whole cell lysates was performed with an anti-IFN-gR1 antibody. The anti-IFN-gR1 antibody detected an identical 90-kDa protein in each of the cell lines, consistent with their expected molecular weight (Figure 3c ). Interferon-g stimulation has no effect on the IFN-gR1 expression levels compared with unstimulated cells. Immunoblotting revealed that the IFN-g receptor component was expressed in SKN cells at similar levels in comparison with HeLa and HeLa.S3 cells (Figure 3c ). Because the SKN cells had relatively comparable surface expressions of the IFN-gR1 chain to HeLa and HeLa.S3 cells, the loss of IFN-g responsiveness in the SKN cells may not be attributable to the inadequate surface expression of this IFN-g signal component. The IHC experiments with antibodies against JAK1 and STAT1 revealed strong positive cells in N.USMC and uterine leiomysarcoma (Supplementary Figure 4) . By contrast, although the phospho-STAT1 was weakly positive in N.USMC, it was essentially negative in uterine leiomysarcoma cells (Supplementary Figure 4) . JAK1 activation was demonstrated to be an essential kinase for the IFN-g inducibility of the tyrosine (Tyr701) phosphorylation and DNA binding of STAT1 (Sexl et al., 2003) . It is likely that IFN-g-inducible LMP2 and TAP1 expressions are impaired due to defects in the JAK1 activation on SKN cells. To evaluate whether the transcriptional response of IFN-g could be rescued in SKN cells, the Jak1 expression vector was transiently transfected into SKN cells. Exogenous JAK1 significantly restored the IFN-g inducibility of TAP1 and LMP2 expression and phospho-STAT1, as detected by immunoblotting (Figure 4) . Thus, the loss of IFN-g responsiveness in the SKN cells may be attributable to the inadequate kinase activity of JAK1 due to intermolecular mutations.
Identification of mutations and no ATP-binding activity of JAK1 in SKN cells
To obtain further evidence indicating the presence of mutations of JAK1, cDNA was generated from the total RNA isolated from the SKN cells. The cDNA fragments of JAK1 were amplified and were then directly sequenced. Comparison of the cDNA sequences (Figure 5a ). The G-to-A base-pair change is predicted to change glycine to glutamic acid at amino-acid position 871 (G871E) in the protein kinase ATP-binding region of the JAK1 tyrosine kinase domain (Figure 5a ). To confirm the functional effect of the mutation located in the ATP-binding region, the ATP-binding activity of JAK1 from all four cell lines were examined with agarose-conjugated ATP. The JAK1 of all four cell lines demonstrated identical levels of expression of total JAK1, suggesting that the presence of the G871E mutation does not substantially alter the production or degradation. The ATP-binding activities of JAK2 were detected in all tested cell lines (Figure 5b ). In contrast, after the mixture with the cytosolic extract isolated from HeLa, HeLa.S3 cells or Hu.USMC, JAK1 was clearly detected in the proteins/ATP complexes, whereas JAK1 was not detected in the proteins/ATP complexes from the cytosolic extract isolated from SKN cells (Figure 5b ). These research findings suggested that the G781E mutation in the protein kinase ATP-binding region resulted in defective tyrosine kinase activity.
Defective interferon-g inducibility of TAP1 and LMP2 due to G781E mutation in the ATP-binding region of JAK1 It is likely that IFN-g-inducible LMP2 and TAP1 expressions are impaired due to the G781E mutation in the ATP-binding region of JAK1 in SKN cells. To evaluate whether the G781E mutation results in the loss of transcriptional response of IFN-g in SKN cells, the wild-type JAK1 (JAK1wt) or JAK1-GE expression vector was transiently transfected into SKN cells. Although exogenous JAK1wt markedly restored the IFN-g inducibility of TAP1 and LMP2 expression and phospho-STAT1, exogenous JAK1-GE did not ( Figure 6 ). Thus, the loss of IFN-g responsiveness in the SKN cells is attributable to the inadequate kinase activity of JAK1 due to G781E mutation in the ATPbinding region.
Discussion
Uterine leiomyosarcomas are relatively rare smooth muscle tumors, having an estimated annual incidence of 0.64 per 100 000 women. They account for approximately one-third of uterine sarcomas and 1.3% of all uterine malignancies, and are considered to be aggressive malignancies with a 5-year survival rate of only 50% for tumors confined to the uterus. To the best of our knowledge, little is known regarding the biology of uterine leiomyosarcomas. Therefore, the risk factors that promote the initial development of uterine leiomyosarcomas and regulate their growth in vivo remain poorly understood.
Although gynecological cancers, for instance breast cancer and endometrial carcinomas, are stongly promoted by female hormones, the rate of estrogen receptor and progesterone receptor expression is reported to be significantly less in uterine leiomyosarcomas compared with normal uterine smooth muscle (USM). These low receptor expressions were found to not correlate with promotion of initial disease development or with overall survival (Leitao et al., 2004) . Dysregulation of apoptotic mechanisms has also been implicated in many human cancers. Although the significant differential expression of apoptotic and cell cycle regulatory factors in uterine leiomyosarcoma, such as bcl-2, bax, p16, p21, p27, c-kit, MDM2 and p53, have all been reported and compared to USM, there exists no scientific evidence to show that abnormal expression of these factors directly correlate to the initiation and promotion of uterine leiomyosarcomas (Leiser et al., 2005; Raspollini et al., 2005) .
The LMP2-deficient mouse exhibits development of uterine leiomyosarcomas (Hayashi and Faustman, 2002) . Furthermore in our experiment, LMP2 mice lost their ability to induce TAP1 and LMP2 expression in SKN cells treated with IFN-g, as shown in Figure 1 , similarly to other primary uterine leiomysarcoma cells 
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(data not shown). This defect was localized to JAK1 activation, which acts upstream in the IFN-g signal pathway since IFN-g treatment could not strongly induce JAK1 kinase activity (Figure 3d ). Immunoblotting revealed that SKN cells clearly expressed IFN-gR (Figure 3c) , and FACS analysis showed that both the IFN-gR1 and b2-m were expressed on the surface of SKN cells (Supplementary Figure 2) . The physiological relevance of the IFN-g-dependent signal cascade through the JAKs-STAT1 pathway, including PI3K, was established by generating and characterizing mice with a targeted disruption of the genes encoding STAT1 or JAK1 (Ihle, 2001; O'Shea et al., 2002; Ramana et al., 2002; Sexl et al., 2003; Platanias, 2005) . Here, sequencing analysis clearly showed that the G-to-A base-pair change was predicted to change glycine to glutamic acid at amino-acid position 871 (G871E) in the ATP-binding region of the JAK1 tyrosine kinase domain (Figure 5a ). The JAK1 derived from SKN cells demonstrated identical expression levels of total JAK1, suggesting that the presence of the G871E mutation did not substantially alter the JAK1 production or degradation. In contrast, JAK1 derived from HeLa, HeLa.S3 and Hu.USMC cells markedly detected the ATP-binding activity of tyrosine protein kinase, whereas JAK1 derived from SKN cells did not completely detect ATP-binding activity (Figure 5b) . It is noteworthy that in SKN cells undergoing transient transfection analysis, exogenous JAK1wt completely restored IFN-g inducibility of TAP1 and LMP2, whereas exogenous JAK1-GE did not (Figure 6 ). The phosphorylation of STAT1 on the tyrosine residue at position 701, which is essential for homodimer formation, is required by JAK1 kinase activity (Sexl et al., 2003) . In a further experiment, a mutation was not detected in the kinase activation region of JAK2 and the phosphorylation residue of ling, which in turn regulates phosphorylation of STAT1 on the serine residue at position 727 (Ser727) required for STAT1 transcriptional activation, seems to work normally in the SKN cell. Thus, the loss of IFN-g responsiveness in the SKN cells is attributable to the inadequate kinase activity of JAK1 due to a G781E mutation. The growth of cell lines that have JAK1 kinase activity have been demonstrated to be strongly inhibited by IFN-g treatment, whereas the growth of JAK1-deficient cell lines is unaffected (Sexl et al., 2003) . Similarly, the cell cycle distribution pattern of freshly explanted tumor cells derived from Jak1-deficient tumors shows no response to IFN-g treatment (Sexl et al., 2003) . In our study, the growth of the original SKN cells, which had defective JAK1 activity, was unaffected by IFN-g treatment (Supplementary Figure  5) . In contrast, the growth of JAK1-transfected SKN cells, which had strong exogenous JAK1 activity, was prevented by IFN-g treatment (Supplementary Figure  5) . Interestingly, when LMP2-transfected SKN cells, which have marked LMP2 expression, were analysed, exogenous LMP2 expression resulted in cell growth inhibition (Supplementary Figure 5) . Conversely, the growth of LMP2-transfected SKN cells was unaffected by IFN-g treatment (Supplementary Figure 5) . Taken together, IFN-g response to cell growth inhibition may be attributable to the IFN-g inducibility of LMP2.
The downregulation of MHC expression, including the TAP1 and LMP2 genes, is one of the biological mechanisms tumor cells use to evade host immunosurveillance (Singal et al., 1996; Dovhey et al., 2000; Cabrera et al., 2003) . Recently, the incidence of IFN-g unresponsiveness in human tumors was examined in several cancers, and revealed that approximately 33% of each group exhibited a reduction in IFN-g sensitivity (Kaplan et al., 1998) . Nevertheless, LMP2 expression, rather than providing an escape from immune surveillance, seems to play an important role in the negative regulation of uterine leiomyosarcoma cell growth. Defective LMP2 expression is likely to be one of the risk factors for the development of human uterine neoplasm, as it is in the LMP2-deficient mouse. Thus, gene therapy with LMP2 expression vectors may be a new treatment for uterine leiomysarcomas that exhibit a defect in LMP2 expression. Because there is no effective therapy for unresectable uterine leiomyosarcoma, our results may bring us to specific molecular therapies to treat this disease. Reverse transcription-polymerase chain reaction analysis The expressions of TAP1, LMP2, b2-m and b-actin transcripts were examined using RT-PCR. Cells were both untreated and treated with 250 U/ml human IFN-g (Pepro Tech, Inc., NJ, USA) for 48 h before the RNA harvest. Total RNA was prepared from 5 Â 10 6 cells using TRIzol reagent according to the manufacturer's protocol (Invitrogen Co., CA, USA). The RNA was reverse-transcribed with the Superscript II enzyme (Invitrogen Co., CA, USA), the single-strand cDNA was used to amplify TAP1, LMP2, b2-m and b-actin transcripts using PCR analysis with the appropriate primer sets following a program of 35 cycles of 941C for 30 s, 601C for 30 s and 721C for 1.5 min with an additional 5 min for the extention of transcripts (Cabrera et al., 2003; Miyagi et al., 2003) .
Materials and methods

Cell lines and media
Immunohistochemistry
Immunohistochemistry was performed using the avidin-biotin complex method previously described (Hsu et al., 1981) . Briefly, one representative 5-mm tissue section was cut from a paraffin-embedded sample of the radical hysterectomy specimen from patients with uterine leiomyosarcoma. Sections were deparaffinized and rehydrated in graded alcohols and then incubated with normal mouse serum for 20 min. Sections were incubated at room temperature for 1 h with anti-LMP2 antibody (Affinity Res. Products Ltd, Exeter, UK; dilution 1/100). Afterwards, sections were incubated with a biotinylated secondary antibody (Dako, Carpinteria, CA, USA) and then exposed to a streptavidin complex (Dako). Complete reaction was revealed by 3,3 0 -diaminobenzidine, and the slide was counterstained with hematoxylin. Normal USM sections from specimens were used as positive controls. Negative controls consisted of tissue sections also incubated with normal rabbit IgG instead of the primary antibody.
Immunoprecipitation and immunoblotting
Cytosolic extracts and nuclear extracts were prepared from 5 Â 10 6 cells, treated and untreated with 250 U/ml human IFNg for the individual times indicated in each figure, essentially as previously described (Brucet et al., 2004) . The cells were harvested for 10 min at 1200 r.p.m., washed in 5 ml of ice-cold PBS and centrifuged for 5 min at 12000 r.p.m. at 41C. The cells were pelleted and washed once in 0.4 ml of buffer A (10 mM Hepes, pH 7.8; 10 mM KCl; 2 mM MgCl 2 ; 1 mM DTT; 0.1 mM EDTA; complete protease inhibitor cocktail (Kirkegaard & Perr Lab., MD, USA)) and incubated for 2 h at 41C. Then, 25 ml of a 10% Nonidert P-40 solution was added, and the cells were vigorously mixed for 1 h at 41C and then centrifuged for 5 min at 12 000 r.p.m.. After the centrifugation, the supernatants were collected as cytosolic extracts and stored at À801C. Pelleted nuclei were resuspended in 40 ml of buffer C (50 mM Hepes, pH 7.8; 50 mM KCl; 300 mM NaCl; 0.1 mM EDTA; 1 mM DTT; 10% (v/v) glycerol), mixed for 2 h at 41C, and centrifuged for 5 min at 12 000 r.p.m. at 41C. The supernatant containing the nuclear proteins was harvested, and then stored at -801C.
In order to detect STAT1, the phospho-STAT1(Try701), JAK1, JAK2, TAP1 and LMP2 expressions, the whole cell lysates or cytosolic extracts were resolved on a 10% SDS-PAGE, and immunoblotting were performed using the standard method with anti-STAT1 antibody, antiphospho-STAT1(Try701) antibody (Santa-Cruz Biotechnologies, CA, USA), anti-JAK1 or JAK2 antibodies (Chemicon Int'l, CA, USA), anti-TAP1 antibody (Stressgen, Canada) or anti-LMP2 antibody (Affiniti Res. Products Ltd., Exeter, UK). For the detection of IRF1 or IRF2 expression, the nuclear extracts were resolved on a 10% SDS-PAGE, and immunoblotting was performed using the standard method with an anti-IRF1 antibody (Transduction Lab., KY, USA) or an anti-IRF2 antibody (Santa-Cruz Biotechnologies, CA, USA). The blots were visualized with the appropriate antibodies indicated in each figure, and subjected to alkaline phosphatase detection analysis according to the manufacturer's protocol (Promega Co., Madison, WI, USA).
Whole cell extracts from 5 Â 10 6 treated and untreated cells, with 250 U/ml IFN-g for the individual times indicated in each figure were lysed in buffer containing 50 mM Tris-HCl, 0.1 mM EDTA, 200 mM NaCl, 10% glycerol, 0.5% NP-40, 1 mM DTT and complete protease inhibitor cocktail (Kirkegaard & Perr Lab., MD, USA). Total cell lysate was pre-cleared with normal rabbit serum (Santa-Cruz Biotechnologies, CA, USA) and 20 ml of protein-G sepharose (Amersham Biosciences, Sweden), then immunoprecipitated with 2 mg of either anti-JAK1 or JAK2 antibodies. The samples were resolved on a 10% SDS-PAGE and transferred onto Immobilon-P. The blots were visualized with a phosphotyrosine antibody 4G10 and alkaline phosphatase detection analysis following the manufacture's protocol (Promega Co., WI, USA). For the detection of IFN-gR1 chain expression, whole cell lysates were resolved as above. The blots were incubated with anti-IFN-gR1 chain antibody (PBL Biomedical Laboratories, NJ, USA). Point mutation in the JAK1 coding sequence (G871E) was constructed using Site-Directed mutagenesis System according to the manufacturer's protocol (Promega Co., WI, USA). The DNA sequence of mutagenic oligonucleotides for the JAK-GE expression vector was as follows; gaggattcgtgacttggaagagggtcactttggg (g2612a). SKN cells were transfected with the pRK5 control (2 mg), JAK1wt expression vector (2 mg) or JAK-GE expression vector (2 mg) (a kind gift from Dr J Ihle, St Jude Children's Research Hospital, Memphis, TN, USA). Interferon-g was added at 24 h after transfection and the cells incubated for an additional 24 h prior to harvesting. Cotransfections with pCMVb-Gal were performed to normalize transfection efficiency.
Electrophoretic mobility shift assay Nuclear extracts were prepared from the treated and untreated cells with IFN-g for the individual times indicated in each figure. Electrophoretic mobility shift assay was performed as previously described (Hayashi et al., 1993) , using DNA probes containing the STAT1-binding sequence or IRF-E. The DNA sequences of these synthetic oligonucleotides for the STAT1-binding site or IRF-E were as follows; STAT1, aagcattcctgtaaggact; IRF-E, ggaagcgaaaatgaaattgact.
Transfections and reporter assay Diagrams of the TAP1 and LMP2 wt (TAP1 593-1/pGL3 and LMP2 1-593/pLG3) and their respective IRF-E mutant Interferon-g (to a final concentration of 250 U/ml) was added 24 h after transfection and the cells were incubated for an additional 24 h. Finally, the cells were washed, lysed in 500 ml of lysis buffer and analysed with a Dual-Luciferase Reporter Assay System (Promega Co., Madison, WI, USA) according to the manufacturer's instructions. The luciferase activity of the cells transfected with pGL3-basic instead of LMP2 or TAP1/pGL3 was subtracted as the background.
Sequencing of the JAK1 gene
To demonstrate the presence of mutations of the JAK1 molecule playing in SKN cells, the isolating of RNA from the SKN cells and sequencing of the resultant cDNA was carried out. Total RNA was extracted from SKN cells with the use of a total RNA extraction miniprep system (VIOGENE, Yrkesuagen, Umea). Then, 800 ng of total RNA was subjected to reverse-transcription PCR with random hexamer primers. Amplification of the cDNA (sense primer: 5 0 atggctttctgtgcta aaatgaggagctcc3 0 , and antisense primer: 5 0 tccactggattccaagatt cccagtcacca3 0 ; sense primer: 5 0 tggtgactgggaatcttggaatccagt g ga3 0 , and antisense primer: 5 0 ccgtaatggggatgccggggtcactga gct3 0 , sense primer: 5 0 agctcagtgaccccggcat ccccattacgg3 0 , and antisense primer: 5 0 ttattttaaaagtgcttcaaatccttcaa3 0 ) yielded three fragments, a 940-, 1290-and 1251-bp fragment. Polymerase chain reaction products were directly sequenced using DYEnamic Terminator Cycle sequencing Kit (Amersham-Biosciences, Piscataway, NJ, USA) by ABI Prism 3100 Genetic Analyzer (Applied Biosystem, Foster City, CA, USA). The sequence of mutant JAK1 derived from SKN cells was registered at DDBJ (accession: AB219242).
JAK1 and JAK2 ATP-binding analysis
The ATP-binding analysis (Hayashi etal., 1993) was performed with the cytosolic extracts obtained from HeLa, HeLa.S3, SKN cells and Hu.USMC. The cytosolic extracts were added to the kination buffer together with agarose conjugated ATP (Sigma-Aldrich Co., MO, USA). Each sample was gently mixed at for 3 h, ATP/protein complexes were precipitated by centrifugation and then were washed with kination buffer at three times. The purified ATP/protein complexes were separated by 10% SDS-PAGE, and immunoblotting were performed using the standard method with JAK1 and JAK2 antibodies. The blots were subjected to an alkaline phosphatase detection system.
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